Cost-utility analysis of operative versus non-operative treatment for colorectal liver metastases

British Journal of Surgery

Volumn 102, Issue 4, 2015, Pages

  Roberts, K J ^a   Sutton, A J ^b   Prasad, K R ^c   Toogood, G J ^c   Lodge, J P A ^c  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; CLINICAL TRIAL; COLORECTAL TUMOR; COMPARATIVE STUDY; ECONOMICS; FEMALE; HUMAN; LIVER NEOPLASMS; MALE; METASTASIS RESECTION; MIDDLE AGED; MULTICENTER STUDY; PALLIATIVE THERAPY; PROBABILITY; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; SECONDARY; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MARKOV CHAINS; METASTASECTOMY; MIDDLE AGED; PALLIATIVE CARE; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84923117454     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9761     Document Type: Article

References (37)

1. McClements PL, Madurasinghe V, Thomson CS, Fraser CG, Carey FA, Steele RJ et al. Impact of the UK colorectal cancer screening pilot studies on incidence, stage distribution and mortality trends. Cancer Epidemiol 2012; 36: e232-e242.
2. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006; 244: 254-259.
3. Pestana C, Reitemeier RJ, Moertel CG, Judd ES, Dockerty MB. The natural history of carcinoma of the colon and rectum. Am J Surg 1964; 108: 826-829.
4. Wagner JS, Adson MA, van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984; 199: 502-508.
5. Wood CB, Gillis CR, Blumgart LH. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 1976; 2: 285-288.
6. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-487.
7. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-766.
8. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318.
9. Jamison RL, Donohue JH, Nagorney DM, Rosen CB, Harmsen WS, Ilstrup DM. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997; 132: 505-510.
10. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71.
11. Pulitanò C, Castillo F, Aldrighetti L, Bodingbauer M, Parks RW, Ferla G et al. What defines 'cure' after liver resection for colorectal metastases? Results after 10 years of follow-up. HPB (Oxford) 2010; 12: 244-249.
12. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25: 4575-4580.
13. Vigano L, Ferrero A, Lo TR, Capussotti L. Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol 2008; 15: 2458-2464.
14. Aballéa S, Boler A, Craig A, Wasan H. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). Eur J Cancer 2007; 43: 1687-1693.
15. Cunningham D, Falk S, Jackson D. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer 2002; 86: 1677-1683.
16. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br J Cancer 2009; 101: 12-18.
17. Shiroiwa T, Fukuda T, Tsutani K. Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan. Int J Clin Oncol 2010; 15: 256-262.
18. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016.
19. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114.
20. Nasti G, Piccirillo MC, Izzo F, Ottaiano A, Albino V, Delrio P et al. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer 2013; 108: 1566-1570.
21. Ducreux M, Adenis A, Pignon JP, Franc¸ois E, Chauffert B, Ichanté JL et al. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Eur J Cancer 2013; 49: 1236-1245.
22. Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012; 17: 15-25.
23. Roberts KJ, White A, Cockbain A, Hodson J, Hidalgo E, Toogood GJ et al. Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases. Br J Surg 2014; 101: 856-866.
24. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25: 4575-4580.
25. Department of Health. 2010-11 Reference Costs Publication. http://wwwdhgovk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-131140 2011 [accessed 1 September 2013].
26. Levi F, Karaboue A, Gorden L, Innominato PF, Saffroy R, Giacchetti S et al. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol 2011; 67: 339-348.
27. National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. NICE: London, 2008.
28. van Dam RM, Wong-Lun-Hing EM, van Breukelen GJ, Stoot JH, van der Vorst JR, Bemelmans MH et al. Open versus laparoscopic left lateral hepatic sectionectomy within an enhanced recovery ERAS® programme (ORANGE II-trial): study protocol for a randomised controlled trial. Trials 2012; 13: 54.
29. Tanis E, Nordlinger B, Mauer M, Sorbye H, van Coevorden F, Gruenberger T et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 2014; 50: 912-919.
30. Iwahashi S, Shimada M, Utsunomiya T, Imura S, Morine Y, Ikemoto T et al. Laparoscopic hepatic resection for metastatic liver tumor of colorectal cancer: comparative analysis of short- and long-term results. Surg Endosc 2014; 28: 80-84.
31. HM Treasury. The Green Book: Appraisal and Evaluation in Central Government. HM Treasury: London, 2011.
32. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-452.
33. Jones RP, Vauthey JN, Adam R, Rees M, Berry D, Jackson R et al. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg 2012; 99: 1263-1269.
34. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 2000; 232: 777-785.
35. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003; 237: 208-217.
36. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 1208-1215.
37. Cauchy F, Aussilhou B, Dokmak S, Fuks D, Gaujoux S, Farges O et al. Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Ann Surg 2012; 256: 746-752.